Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Orthofix International NV (OFIX)?

Page 1 of 2

In today’s marketplace, there are dozens of indicators investors can use to monitor publicly traded companies. A pair of the most under-the-radar are hedge fund and insider trading sentiment. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite hedge fund managers can outperform the S&P 500 by a very impressive amount (see just how much).

Orthofix International NV (NASDAQ:OFIX)

Just as crucial, bullish insider trading activity is another way to analyze the investments you’re interested in. There are a number of reasons for a bullish insider to downsize shares of his or her company, but only one, very simple reason why they would behave bullishly. Several academic studies have demonstrated the valuable potential of this method if shareholders understand where to look (learn more here).

What’s more, let’s study the latest info for Orthofix International NV (NASDAQ:OFIX).

What have hedge funds been doing with Orthofix International NV (NASDAQ:OFIX)?

Heading into Q3, a total of 15 of the hedge funds we track held long positions in this stock, a change of 25% from the previous quarter. With hedgies’ sentiment swirling, there exists an “upper tier” of key hedge fund managers who were increasing their holdings significantly.

Out of the hedge funds we follow, Diamond Hill Capital, managed by Ric Dillon, holds the biggest position in Orthofix International NV (NASDAQ:OFIX). Diamond Hill Capital has a $18.4 million position in the stock, comprising 0.2% of its 13F portfolio. On Diamond Hill Capital’s heels is Jay Petschek and Steven Major of Corsair Capital Management, with a $13.4 million position; 1.7% of its 13F portfolio is allocated to the company. Remaining hedgies with similar optimism include Cliff Asness’s AQR Capital Management, Jacob Gottlieb’s Visium Asset Management and David Dreman’s Dreman Value Management.

As industrywide interest increased, particular hedge funds were breaking ground themselves. Diamond Hill Capital, managed by Ric Dillon, created the largest position in Orthofix International NV (NASDAQ:OFIX). Diamond Hill Capital had 18.4 million invested in the company at the end of the quarter. Jay Petschek and Steven Major’s Corsair Capital Management also made a $13.4 million investment in the stock during the quarter. The other funds with new positions in the stock are Cliff Asness’s AQR Capital Management, Jacob Gottlieb’s Visium Asset Management, and David Dreman’s Dreman Value Management.

How have insiders been trading Orthofix International NV (NASDAQ:OFIX)?

Bullish insider trading is particularly usable when the primary stock in question has seen transactions within the past 180 days. Over the latest 180-day time frame, Orthofix International NV (NASDAQ:OFIX) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Orthofix International NV (NASDAQ:OFIX). These stocks are MAKO Surgical Corp. (NASDAQ:MAKO), The Spectranetics Corporation (NASDAQ:SPNC), NxStage Medical, Inc. (NASDAQ:NXTM), ABIOMED, Inc. (NASDAQ:ABMD), and Greatbatch Inc (NYSE:GB). This group of stocks belong to the medical appliances & equipment industry and their market caps are closest to OFIX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!